Tags

Type your tag names separated by a space and hit enter

Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study.
J Clin Gastroenterol 2011; 45(6):518-25JC

Abstract

BACKGROUND

Recent data suggest a role for the intestinal microbiota in the pathogenesis of functional bowel disorders (FBDs). Probiotic studies in FBDs generated inconsistent results suggesting a strain-specific and product-specific effect.

AIM

To investigate the clinical efficacy of Lactobacillus acidophilus NCFM (L-NCFM) and Bifidobacterium lactis Bi-07 (B-LBi07) in nonconstipation FBDs.

METHODS

A double-blind, placebo-control clinical trial of the probiotic bacterias L-NCFM and B-LBi07 twice a day (2×10(11) CFU/d) versus placebo over 8 weeks. Primary endpoints were global relief of gastrointestinal symptoms and satisfaction with treatment. Secondary endpoints were change in symptoms severity, well-being, and quality of life. Microbiological effect was assessed by quantitative real time polymerase chain reaction on fecal samples.

RESULTS

Sixty patients (probiotic, n=31; placebo, n=29), 72% females, 84% whites, mean age 37 years. Abdominal bloating improved in the probiotics compared with the placebo group at 4 weeks (4.10 vs 6.17, P=0.009; change in bloating severity P=0.02) and 8 weeks (4.26 vs 5.84, P=0.06; change in bloating severity P<0.01). Analyses on the irritable bowel syndrome subgroup (n=33) showed similar results.

CONCLUSIONS

L-NCFM and B-LBi07 twice a day improve symptoms of bloating in patients with FBDs. These data supports the role of intestinal bacteria in the pathophysiology of FBD and the role for probiotic bacteria in the management of these disorders.

Authors+Show Affiliations

Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21436726

Citation

Ringel-Kulka, Tamar, et al. "Probiotic Bacteria Lactobacillus Acidophilus NCFM and Bifidobacterium Lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients With Functional Bowel Disorders: a Double-blind Study." Journal of Clinical Gastroenterology, vol. 45, no. 6, 2011, pp. 518-25.
Ringel-Kulka T, Palsson OS, Maier D, et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol. 2011;45(6):518-25.
Ringel-Kulka, T., Palsson, O. S., Maier, D., Carroll, I., Galanko, J. A., Leyer, G., & Ringel, Y. (2011). Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. Journal of Clinical Gastroenterology, 45(6), pp. 518-25. doi:10.1097/MCG.0b013e31820ca4d6.
Ringel-Kulka T, et al. Probiotic Bacteria Lactobacillus Acidophilus NCFM and Bifidobacterium Lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients With Functional Bowel Disorders: a Double-blind Study. J Clin Gastroenterol. 2011;45(6):518-25. PubMed PMID: 21436726.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. AU - Ringel-Kulka,Tamar, AU - Palsson,Olafur S, AU - Maier,Danielle, AU - Carroll,Ian, AU - Galanko,Joseph A, AU - Leyer,Gregory, AU - Ringel,Yehuda, PY - 2011/3/26/entrez PY - 2011/3/26/pubmed PY - 2011/10/18/medline SP - 518 EP - 25 JF - Journal of clinical gastroenterology JO - J. Clin. Gastroenterol. VL - 45 IS - 6 N2 - BACKGROUND: Recent data suggest a role for the intestinal microbiota in the pathogenesis of functional bowel disorders (FBDs). Probiotic studies in FBDs generated inconsistent results suggesting a strain-specific and product-specific effect. AIM: To investigate the clinical efficacy of Lactobacillus acidophilus NCFM (L-NCFM) and Bifidobacterium lactis Bi-07 (B-LBi07) in nonconstipation FBDs. METHODS: A double-blind, placebo-control clinical trial of the probiotic bacterias L-NCFM and B-LBi07 twice a day (2×10(11) CFU/d) versus placebo over 8 weeks. Primary endpoints were global relief of gastrointestinal symptoms and satisfaction with treatment. Secondary endpoints were change in symptoms severity, well-being, and quality of life. Microbiological effect was assessed by quantitative real time polymerase chain reaction on fecal samples. RESULTS: Sixty patients (probiotic, n=31; placebo, n=29), 72% females, 84% whites, mean age 37 years. Abdominal bloating improved in the probiotics compared with the placebo group at 4 weeks (4.10 vs 6.17, P=0.009; change in bloating severity P=0.02) and 8 weeks (4.26 vs 5.84, P=0.06; change in bloating severity P<0.01). Analyses on the irritable bowel syndrome subgroup (n=33) showed similar results. CONCLUSIONS: L-NCFM and B-LBi07 twice a day improve symptoms of bloating in patients with FBDs. These data supports the role of intestinal bacteria in the pathophysiology of FBD and the role for probiotic bacteria in the management of these disorders. SN - 1539-2031 UR - https://www.unboundmedicine.com/medline/citation/21436726/Probiotic_bacteria_Lactobacillus_acidophilus_NCFM_and_Bifidobacterium_lactis_Bi_07_versus_placebo_for_the_symptoms_of_bloating_in_patients_with_functional_bowel_disorders:_a_double_blind_study_ L2 - http://Insights.ovid.com/pubmed?pmid=21436726 DB - PRIME DP - Unbound Medicine ER -